UPC 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue

Jinggangshan Economic and Technological DevelopmentZone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Exhibits

1

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

2

Exhibit 99.1

Universe Pharmaceuticals INC Announces Effective Date of Dual-ClassShare Structure

Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026.

In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company’s authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of par value US$0.00001 each (the “Class A Ordinary Shares”) and 200,000,000 class B ordinary shares of par value US$0.00001 each.

The Company anticipates that beginning with the opening of trading on February 13, 2026, the Class A Ordinary Shares will trade on the Nasdaq Capital Market under the same symbol “UPC” and the same CUSIP number G9442G 138.

About Universe Pharmaceuticals INC

Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.

Forward-Looking Statements

This press release contains forward-lookingstatements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projectionsabout future events and financial trends that the Company believes may affect its financial condition, results of operations, businessstrategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,”“expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,”“potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes noobligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations,except to the extent required by law. Although the Company believes that the expectations expressed in these forward-looking statementsare reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actualresults may differ materially from the anticipated results and encourages investors to review other factors that may affect its futureresults in the Company’s most recent annual report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Ms. Lin Yang

Chief Financial Officer of Universe Pharmaceuticals INC

[email protected]